Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs SoundHound AI Inc (SOUN) Price & Performance

BioNTech SE - ADRTrade
SoundHound AI IncTrade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs SoundHound AI Inc — how do they compare? BioNTech SE - ADR trades at $90 (market cap $22.86B), while SoundHound AI Inc trades at $6.54 (market cap $2.91B). The key difference: BioNTech SE - ADR is far larger — about 7.9× SoundHound AI Inc's market cap, and BioNTech SE - ADR is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals.

BNTXSOUN
Market Cap
$22.86B$2.91B
Sector
HealthTechnology
52-Week High
$119.34$21.40
52-Week Low
$83.89$5.90
Enterprise Value
$6.53B$2.71B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.

The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.

SoundHound AI Inc

SoundHound AI (SOUN) trades at $6.49, down 2.26% on the day and 37% year-to-date, reflecting investor concerns over persistent losses despite strong revenue growth. The stock shows a bearish technical trend with neutral oscillators, while fundamentals reveal a high P/S of 15.03 and negative net income margin of -91.84%. Recent positive developments include being named a Leader in Gartner's Magic Quadrant for Conversational AI Platforms (GlobeNewsWire, July 13, 2026) and beating EPS estimates in three consecutive quarters.

The outlook remains high-risk with significant cash burn and execution challenges, but analyst consensus is bullish with a $13 price target (75% buy ratings). Investment opportunity hinges on successful integration of acquisitions like LivePerson and expansion into telecom/energy markets, though volatility from short interest and profitability concerns pose substantial downside risk.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About SoundHound AI Inc

SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.

Read more on SOUN